Sab Biotherapeutics, Inc. (SABSW) SEC Filings — 2024
21 SEC filings for Sab Biotherapeutics, Inc. (SABSW) in 2024.
Filings
- SAB Biotherapeutics Q3 2024: Grant Revenue and Warrant Details — 10-Q · Nov 6, 2024
- SAB Biotherapeutics Files 8-K with Financials and Warrant Details — 8-K · Sep 9, 2024
- SAB Biotherapeutics Files Q2 2024 10-Q Report — 10-Q · Aug 8, 2024
- SAB Biotherapeutics Files 8-K on Officer/Director Changes — 8-K · Jul 31, 2024
- SAB Biotherapeutics Files 8-K on Security Holder Vote Matters — 8-K · Jun 27, 2024
- SAB Biotherapeutics: Director Departs, New Director Elected — 8-K · May 31, 2024
- SAB Biotherapeutics Files Definitive Proxy Statement — DEF 14A · May 30, 2024
- SAB Biotherapeutics Files 8-K — 8-K · May 21, 2024
- SAB Biotherapeutics Reports Q1 Grant Revenue, Details Warrant Activity — 10-Q · May 20, 2024
- SAB Biotherapeutics Files 8-K on Officer/Director Changes — 8-K · May 8, 2024
- SAB Biotherapeutics Files 8-K on Stock and Warrants — 8-K · Apr 15, 2024
- SAB Biotherapeutics, Inc. Files 2023 Annual Report on Form 10-K — 10-K · Mar 29, 2024
- SAB Biotherapeutics Announces Director Change and Filings — 8-K · Mar 8, 2024
- Sab Biotherapeutics, Inc. SC 13G/A Filing — SC 13G/A · Feb 14, 2024
- Sab Biotherapeutics, Inc. SC 13G/A Filing — SC 13G/A · Feb 14, 2024
- Sab Biotherapeutics, Inc. SC 13G Filing — SC 13G · Feb 14, 2024
- SAB Biotherapeutics Converts All Warrants to Common Stock — 8-K · Feb 2, 2024
- SABS Enters Material Agreement for Stock & Warrants at $11.50 Exercise Price — 8-K · Jan 26, 2024
- SAB Biotherapeutics Confirms Nasdaq Listing for Stock & Warrants — 8-K · Jan 25, 2024
- SAB Biotherapeutics Confirms Nasdaq Listing, Warrant Details — 8-K · Jan 19, 2024
- SAB Biotherapeutics Amends Bylaws, Modifies Security Holder Rights — 8-K · Jan 3, 2024